Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520906-36-00

Enrollment

120

Registered

2026-05-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Brief summary

ADHD symptoms, Emotion regulation, Sleep

Detailed description

Pharmacokinetic profile, Theta-beta power ratio, CYP2D6 functionality, Polygenic risk score

Interventions

DRUGD-lysergic acid diethylamide (LSD)

DRUG1mL of ethanol

DRUG95% Vol.

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
ADHD symptoms, Emotion regulation, Sleep	—

Secondary

Measure	Time frame
Pharmacokinetic profile, Theta-beta power ratio, CYP2D6 functionality, Polygenic risk score	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 12, 2026